StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVTGet Rating) in a research report report published on Tuesday. The firm issued a sell rating on the stock.

Separately, Kepler Capital Markets raised shares of DBV Technologies from a hold rating to a buy rating and set a €6.00 ($6.12) price objective on the stock in a research note on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $5.63.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $1.38 on Tuesday. The stock has a market cap of $259.51 million, a P/E ratio of -2.51 and a beta of 1.43. The stock has a 50 day simple moving average of $1.65 and a two-hundred day simple moving average of $1.98. DBV Technologies has a fifty-two week low of $1.15 and a fifty-two week high of $3.43.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DBVT. RA Capital Management L.P. purchased a new position in DBV Technologies in the third quarter worth about $6,593,000. Vivo Capital LLC purchased a new stake in DBV Technologies in the third quarter worth $4,795,000. Fairmount Funds Management LLC lifted its holdings in DBV Technologies by 46.2% during the 3rd quarter. Fairmount Funds Management LLC now owns 7,064,964 shares of the company’s stock valued at $12,505,000 after buying an additional 2,233,809 shares in the last quarter. ExodusPoint Capital Management LP bought a new position in DBV Technologies in the 2nd quarter worth about $352,000. Finally, BlackRock Inc. grew its stake in DBV Technologies by 16.5% in the first quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock worth $1,093,000 after purchasing an additional 97,412 shares in the last quarter. 27.55% of the stock is owned by institutional investors.

About DBV Technologies

(Get Rating)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.

Further Reading

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.